Legal & Disputes
Kahn Swick & Foti Opens Investigation Into QuidelOrtho Officers Over Savanna RVP4 Claims
By News Desk ·
Key takeaways
- Kahn Swick & Foti has commenced an investigation into whether QuidelOrtho's officers or directors breached fiduciary duties to shareholders.
- A securities class action alleges Savanna RVP4 invalid test rates of 10% to 30%, against an industry standard of 1% to 2%.
- The lawsuit alleges QuidelOrtho doubled its endemic COVID-19 revenue guidance to $200 million to $400 million without supporting data.
Kahn Swick & Foti, LLC has commenced an investigation into QuidelOrtho Corporation's officers and directors, the firm said in a PR Newswire announcement dated November 20, 2026. The inquiry follows a securities class action alleging serious problems with the company's Savanna Respiratory Viral Panel 4 test.
What The Savanna RVP4 Lawsuit Alleges
QuidelOrtho is a San Diego-based in vitro diagnostics company serving clinical labs, hospitals, blood banks and point-of-care settings with more than 550 assays across 140-plus countries. The lawsuit, as described by Kahn Swick & Foti, claims the European launch of the Savanna RVP4 was plagued by high rates of invalid test results, device failures and mounting customer complaints, with between 60% and 80% of European customer feedback negative.
The complaint alleges Savanna's invalid test rate ran between 10% and 30%, against an industry standard of 1% to 2%, and that roughly one in four instruments sold in Europe had to be replaced. It also claims the product could not consistently meet the FDA's sensitivity requirements and that manufacturing yields fell far below internal targets, with former employees describing scrap rates of 50% to 80%.
The lawsuit further alleges QuidelOrtho doubled its endemic COVID-19 revenue guidance, from $150 million to $200 million up to $200 million to $400 million, without supporting data, even as internal reports showed declining sales and accumulating inventory. KSF said its investigation is focused on whether QuidelOrtho's officers or directors breached their fiduciary duties to shareholders or otherwise violated state or federal laws. Charles C. Foti, Jr., a partner at the firm and former Attorney General of Louisiana, announced the investigation.
QuidelOrtho's Recent Deal And Finance Moves
According to akta.pro company records, QuidelOrtho completed the acquisition of LEX Diagnostics for approximately $100 million in cash in April 2026, adding the FDA-cleared LEX VELO ultra-fast PCR platform to its molecular diagnostics portfolio. The same records show the company appointed Micah Young as Chief Financial Officer effective July 6, 2026, succeeding retiring CFO Joseph M. Busky. QuidelOrtho's FY2025 total revenues were $2.73 billion, a 2% decrease from the prior year, and Q1 2026 revenue was $620 million, a 10.5% decline compared with the prior year period.
Earlier QuidelOrtho Coverage
On November 13, 2026, American Banking and Market News compared QuidelOrtho with Avita Medical on valuation, profitability and analyst ratings, noting QuidelOrtho's higher revenue of $2.73 billion against Avita's $71.6 million but lower earnings. On November 3, 2026, the same outlet reported that a financial comparison of QuidelOrtho with healthcare equipment rivals showed it lost 8 of 13 factors, including lower profitability and higher risk. On October 27, 2026, MarketBeat reported that QuidelOrtho was expected to post Q3 2026 earnings after market close on November 3, with analysts projecting earnings per share of $0.2023 and revenue of $627.83 million.
What Comes Next For QuidelOrtho
Kahn Swick & Foti said shareholders who have held QuidelOrtho shares long term can contact the firm to discuss their legal rights, and that anyone with information relevant to the investigation can reach it through the case page on its website.